Piper Sandler Reiterates Overweight on Tandem Diabetes Care, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) and raised the price target from $50 to $55.
August 02, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Tandem Diabetes Care and increased the price target from $50 to $55, indicating a positive outlook on the stock.
The reiteration of an Overweight rating and the increase in the price target from $50 to $55 by Piper Sandler suggests a positive outlook for Tandem Diabetes Care. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100